Arvinas to out-license ARV-806 after completing Phase 1 dose escalation

ARVINAS, INC.

Completed dose escalation enrollment for ARV-806 Phase 1 trial in KRAS G12D solid tumors.
Will complete monotherapy dose escalation and share clinical data in 2026.
Plans to seek out-licensing agreement for any additional ARV-806 trials.
Cash, equivalents and marketable securities as of March 31, 2026 fund operations into H2 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.